JP2023536855A - 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド - Google Patents

小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド Download PDF

Info

Publication number
JP2023536855A
JP2023536855A JP2023506031A JP2023506031A JP2023536855A JP 2023536855 A JP2023536855 A JP 2023536855A JP 2023506031 A JP2023506031 A JP 2023506031A JP 2023506031 A JP2023506031 A JP 2023506031A JP 2023536855 A JP2023536855 A JP 2023536855A
Authority
JP
Japan
Prior art keywords
lomitapide
patient
weeks
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023506031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536855A5 (https=
Inventor
ルース・ナレン
トレイシー・カニンガム
マーク・スメレイ
Original Assignee
アムリット・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムリット・ファーマシューティカルズ・インコーポレイテッド filed Critical アムリット・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2023536855A publication Critical patent/JP2023536855A/ja
Publication of JP2023536855A5 publication Critical patent/JP2023536855A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023506031A 2020-07-29 2021-07-29 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド Pending JP2023536855A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063058211P 2020-07-29 2020-07-29
US63/058,211 2020-07-29
PCT/US2021/043667 WO2022026684A1 (en) 2020-07-29 2021-07-29 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Publications (2)

Publication Number Publication Date
JP2023536855A true JP2023536855A (ja) 2023-08-30
JP2023536855A5 JP2023536855A5 (https=) 2024-08-06

Family

ID=77398685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506031A Pending JP2023536855A (ja) 2020-07-29 2021-07-29 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド

Country Status (10)

Country Link
US (3) US20230285376A1 (https=)
EP (1) EP4188372A1 (https=)
JP (1) JP2023536855A (https=)
KR (1) KR20230047381A (https=)
CN (1) CN116322682A (https=)
AU (1) AU2021316011A1 (https=)
BR (1) BR112023000808A2 (https=)
CA (1) CA3186856A1 (https=)
MX (1) MX2023001202A (https=)
WO (1) WO2022026684A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (https=) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
ATE60571T1 (de) 1984-12-04 1991-02-15 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
KR900001212B1 (ko) 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US4716175A (en) 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
ES2009918A6 (es) 1987-05-22 1989-10-16 Squibb & Sons Inc Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo.
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
KR930005040B1 (ko) 1989-08-31 1993-06-12 주식회사 금성사 식기 건조기 겸용 전자레인지 및 그 구동제어방법
US5026554A (en) 1990-09-13 1991-06-25 Merck & Co., Inc. Method of inhibiting fungal growth using squalene synthetase inhibitors
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
DE4435477A1 (de) 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5536859A (en) 1995-02-27 1996-07-16 Amoco Corporation Alpha-olefin catalyst and process
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
PT832069E (pt) 1995-06-07 2003-06-30 Pfizer Derivados de tetrahidro-isoquinolin-6-il amida do acido bifenilo-2-carboxilico sua preparacao e sua utilizacao como inibidores de proteina de transferencia de triglicerido microsomal e/ou da secrecao de apolipoproteina b (apo b)
DE19546919A1 (de) 1995-12-15 1997-06-19 Bayer Ag N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19546918A1 (de) 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
NZ330216A (en) 1996-01-16 2000-09-29 Bristol Myers Squibb Co Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and use in treatment of atherosclerosis
DE19613550A1 (de) 1996-04-04 1997-10-09 Bayer Ag Neue Pyrimido[1,2-a]indole
US6774236B1 (en) 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
DE19613549A1 (de) 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
DE19615265A1 (de) 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
TR199802163T2 (xx) 1996-04-30 1999-02-22 Pfizer Inc. 4'-Triflorometilbifenil-2-karboksilik asit
US6057339A (en) 1996-05-09 2000-05-02 Bristol-Myers Squibb Company Method of inhibiting or treating phytosterolemia with an MTP inhibitor
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0954313A4 (en) 1996-07-24 2003-07-02 Bristol Myers Squibb Co METHOD FOR TREATING TUMORS WITH LOW DENSITY LIPOPROTEIN (LDL) NEEDS USING MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
EA001539B1 (ru) 1996-11-27 2001-04-23 Пфайзер Инк. Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр)
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
AU5513298A (en) 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
WO1998031225A1 (en) 1997-01-17 1998-07-23 Bristol-Myers Squibb Company A method of inhibiting or treating phytosterolemia with an mtp inhibitor
WO1998031366A1 (en) 1997-01-17 1998-07-23 Bristol-Myers Squibb Company Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
EP1024804A4 (en) 1997-05-01 2001-03-21 Bristol Myers Squibb Co MTP INHIBITORS AND FAT-SOLUBLE VITAMIN THERAPEUTICS TO REDUCE SERUM LIPIDS
US5990110A (en) 1997-07-15 1999-11-23 Bristol-Meyers Squibb Company Method for treating tumors having high LDL requirements employing MTP inhibitors
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US20020045271A1 (en) 1998-06-10 2002-04-18 Licata And Tyrrell P.C. Compounds and methods for identifying compounds that interact with microsomal triglyceride transfer protein binding sites on apolipoprotein b and modulate lipid biosynthesis
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
GEP20033045B (en) 1998-09-17 2003-08-25 Bristol Myers Squibb Co Method for Treating Diabetes
US6509348B1 (en) 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
IL133201A0 (en) 1998-12-04 2001-03-19 Pfizer Prod Inc Lowering blood levels of lipoproten (a)
KR20020002367A (ko) 1998-12-23 2002-01-09 윌리암스 로저 에이 심혈관 징후를 위한 조합물
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
PT1033364E (pt) 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
JP2003505504A (ja) 1999-07-30 2003-02-12 バーケイド，ヘンドリク・ジヤン 糞便による脂肪排泄を増加することによる、非ステロール性内因性疎水性物質の排泄を増加する方法
DE19951022A1 (de) 1999-10-22 2001-04-26 Bayer Ag Carbolinderivate
IL139450A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6812345B2 (en) 2000-06-15 2004-11-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
DE10030375A1 (de) 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
US6649770B1 (en) 2000-11-27 2003-11-18 Ciba Specialty Chemicals Corporation Substituted 5-aryl-2-(2-hydroxyphenyl)-2H-benzotriazole UV absorbers, compositions stabilized therewith and process for preparation thereof
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
JP2002220345A (ja) 2001-01-24 2002-08-09 Sumitomo Pharmaceut Co Ltd 脂肪肝改善剤
IL156585A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
KR100575944B1 (ko) 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US6916813B2 (en) 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US20030162788A1 (en) 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
JP3662566B2 (ja) 2002-02-28 2005-06-22 日本たばこ産業株式会社 エステル化合物及びその医薬用途
EP1479666A4 (en) 2002-02-28 2010-10-13 Japan Tobacco Inc ESTER CONNECTION AND THEIR MEDICAL USE
BR0312503A (pt) 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
BR0312825A (pt) 2002-07-23 2005-04-19 Basf Ag Mistura herbicida sinérgica, composição herbicida, processo para a preparação da mesma, e, método de controle de vegetação indesejada
WO2004028544A1 (en) 2002-09-25 2004-04-08 Novo Nordisk A/S Use of mas-compounds for treating diseases associated with lipid metabolism
US20050090426A1 (en) 2003-03-24 2005-04-28 Blumberg Richard S. Methods of inhibiting inflammation
US6846836B2 (en) 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
WO2005000217A2 (en) 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
EP1635773A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. (a New Jersey corp.) Combination therapy for the treatment of hypertension
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
WO2005018436A2 (en) 2003-08-26 2005-03-03 The Trustees Of Boston University Methods for the diagnosis, prognosis and treatment of metabolic syndrome
JP4832897B2 (ja) 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
US7153976B2 (en) 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
MXPA06004005A (es) 2003-10-08 2006-06-28 Vertex Pharma Moduladores de transportadores con casete de union con atp.
ATE428411T1 (de) 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
WO2005051382A1 (ja) 2003-11-28 2005-06-09 Astellas Pharma Inc. 脂質低下作用増強剤
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP2007526309A (ja) 2004-03-02 2007-09-13 アベール ファーマシューティカルズ インコーポレイテッド 生物活性剤の混合製剤またはキット
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
WO2005085466A2 (en) 2004-03-09 2005-09-15 Bayer Healtcare Ag Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
GB0405459D0 (en) 2004-03-11 2004-04-21 Shea Clayton O Skipping ropes
WO2005094864A2 (en) 2004-03-30 2005-10-13 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis
AU2005230397B2 (en) 2004-04-09 2010-04-08 Elanco Animal Health Ireland Limited Intermittent dosing regimen for the treatment of overweight with MTP-inhibitors
JP4782991B2 (ja) 2004-06-30 2011-09-28 株式会社東芝 情報処理機器および情報処理機器の表示制御方法
JP2008505176A (ja) 2004-06-30 2008-02-21 コンビナトアールエックス インコーポレーティッド 代謝障害を治療するための方法および試薬
KR20070072888A (ko) 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
CA2589654C (en) 2004-12-06 2016-02-16 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
CA2584845C (en) 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
WO2006108666A1 (en) 2005-04-13 2006-10-19 Proteosys Ag Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
FR2884831B1 (fr) 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
EP1890767A2 (en) 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
MX2008003432A (es) 2005-09-13 2008-03-27 Bayer Cropscience Ag Derivados plaguicidas de bifenilamidina.
AU2006304689A1 (en) 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
US20080051427A1 (en) 2006-05-18 2008-02-28 Fritz Schuckler Pharmaceutical Compositions and Methods of Using Same
US20090042835A1 (en) 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
CA2654183A1 (en) 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
CA2654098A1 (en) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20080016127A1 (en) 2006-06-30 2008-01-17 Microsoft Corporation Utilizing software for backing up and recovering data
DE102006034907A1 (de) 2006-07-28 2008-01-31 Carl Zeiss Microimaging Gmbh Laser-Scanning-Mikroskop
US20080033019A1 (en) 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
WO2008021353A2 (en) 2006-08-14 2008-02-21 Guangxiang Luo Composition and method for controlling hepatitis c virus infection
US20080103122A1 (en) 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008072061A1 (en) 2006-12-14 2008-06-19 Pfizer Products Inc. Method of treatment of obesity with an mtp inhibitor in conjunction with an increased-fat diet
WO2008075949A1 (en) 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
JP2010513534A (ja) 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
US7645732B2 (en) 2007-01-24 2010-01-12 Board Of Regents, The University Of Texas System Treating hepatitis C virus infection
WO2008090198A1 (en) 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
WO2008115574A1 (en) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
FR2922945B1 (fr) 2007-10-31 2009-11-27 Peugeot Citroen Automobiles Sa Procede de determination d'intervalle de maintenance pour vehicule automobile.
WO2010083280A2 (en) 2009-01-14 2010-07-22 Aegerion Pharmaceuticals, Inc. Methods for treating obesity and disorders associated with hyperlipidemia in a mammal
WO2012010212A1 (en) 2010-07-23 2012-01-26 Prysmian S.P.A. Bend-resistant single-mode optical fibre
HK1224186A1 (zh) * 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
BR102015025502B1 (pt) 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
US20170246133A1 (en) * 2016-02-26 2017-08-31 Gemphire Therapeutics Inc. Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
US20180250251A1 (en) * 2016-02-26 2018-09-06 Gemphire Therapeutics Inc. Treatment of Patients with Familial Hypercholesterolemia on Lipid-Lowering Therapy
FI3448426T3 (fi) 2016-04-28 2025-07-18 Regeneron Pharma Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon
CN107773561A (zh) * 2016-08-24 2018-03-09 天津市汉康医药生物技术有限公司 一种甲磺酸洛美他派胶囊及其制备方法
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
CA3208189A1 (en) 2021-03-03 2022-09-09 Mark SUMERAY Methods for treating familial chylomicronemia syndrome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ICH E11(R1) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC POLPULATION, JPN6025036929, 2017, ISSN: 0005817837 *
JOURNAL OF CLINICAL LIPIDOLOGY, vol. 13, JPN6025036927, 2019, pages 397 - 401, ISSN: 0005817835 *
JUXTAPID(R) (LOMITAPIDE) CAPSULES, LABELING INFORMATION, JPN6025036928, 2019, ISSN: 0005817836 *
THE JOURNAL OF CLINICAL PHARMACOLOGY, vol. 57, no. 4, JPN6025036931, 2017, pages 469 - 475, ISSN: 0005817838 *

Also Published As

Publication number Publication date
WO2022026684A1 (en) 2022-02-03
US20240058317A1 (en) 2024-02-22
CN116322682A (zh) 2023-06-23
US20260021087A1 (en) 2026-01-22
BR112023000808A2 (pt) 2023-02-07
EP4188372A1 (en) 2023-06-07
KR20230047381A (ko) 2023-04-07
MX2023001202A (es) 2023-02-23
US20230285376A1 (en) 2023-09-14
US12472172B2 (en) 2025-11-18
CA3186856A1 (en) 2022-02-03
AU2021316011A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
US11110074B2 (en) Methods of improving the pharmacokinetics of doxepin
US6323188B1 (en) Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins
US20240293394A1 (en) Methods for treating antipsychotic-induced weight gain
TWI618536B (zh) 於納曲酮療法中增加藥物生物可利用性
US20260021087A1 (en) Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
JP6511492B2 (ja) 女性胃不全麻痺に関係する症状の処置
AU2009201201A1 (en) Novel pharmaceutical composition
RU2852098C1 (ru) Ломитапид для применения в способах лечения гиперлипидемии и гиперхолестеринемии у педиатрических пациентов
HK40086374A (zh) 在治疗儿科患者的高脂血症和高胆固醇血症的方法中使用的洛美他派
CN114929229A (zh) 用米立可兰治疗抗精神病药导致的体重增加的方法
Giruzzi Medications for the Management of Obesity
US20100286200A1 (en) Combination of metformin and an mtp inhibitor
US20090280171A1 (en) Method of treatment with predictably breakable pharmaceutical tablets
DK201200198Y4 (da) Sammensætninger indeholdende cetilistat
Hussar New drugs06, part II
EGNAVITIE SAIFIER PREGNANCY
EFFEXOR HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EFFEXOR XR safely and effectively. See full prescribing information for
LITTLE AlloJpurinol in1 Single Daily Dose
HK1180543A (en) Methods for treating antipsychotic-induced weight gain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251209

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260317